$0.45
4.23% today
Nasdaq, Sep 16, 08:14 pm CET
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

FibroGen, Inc. Stock price

$0.47
+0.08 20.51% 1M
-1.53 76.50% 6M
-0.42 46.97% YTD
-0.46 49.26% 1Y
-11.26 95.99% 3Y
-41.02 98.87% 5Y
-21.53 97.86% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.05 11.03%
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

Key metrics

Market capitalization $47.19m
Enterprise Value $112.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.65
P/S ratio (TTM) P/S ratio 0.27
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 33.11%
Revenue (TTM) Revenue $173.82m
EBIT (operating result TTM) EBIT $-147.05m
Free Cash Flow (TTM) Free Cash Flow $-202.99m
Cash position $140.71m
EPS (TTM) EPS $-1.71
P/E forward negative
P/S forward 0.27
EV/Sales forward 0.64
Short interest 6.01%
Show more

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a FibroGen, Inc. forecast:

1x Hold
33%
2x Sell
67%

Analyst Opinions

3 Analysts have issued a FibroGen, Inc. forecast:

Hold
33%
Sell
67%

Financial data from FibroGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
148 148
5% 5%
100%
- Direct Costs 19 19
7% 7%
13%
129 129
7% 7%
87%
- Selling and Administrative Expenses 105 105
8% 8%
71%
- Research and Development Expense 283 283
5% 5%
191%
-259 -259
11% 11%
-175%
- Depreciation and Amortization 9.93 9.93
6% 6%
7%
EBIT (Operating Income) EBIT -269 -269
11% 11%
-182%
Net Profit -284 -284
3% 3%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

FibroGen, Inc. Stock News

Neutral
Seeking Alpha
about one month ago
FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chief Executive Officer Deyaa Adib - Chief Medical Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Dalton Greenwood - W...
Negative
InvestorPlace
about 2 months ago
FibroGen (NASDAQ: FGEN ) layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. FibroGen says that it is going into a cost-saving mode that will result in layoffs for 75% of its U.S. employees.
Negative
InvestorPlace
about 2 months ago
FibroGen (NASDAQ: FGEN ) stock is falling hard on Wednesday after the biopharmaceutical company reported results from failed clinical trials. The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab.
More FibroGen, Inc. News

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Thane Wettig
Employees 486
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today